Where others have failed will Atl1102 succeed ?, page-73

Lets say all goes to plan. Whay Market cap to you see in that 24 to 36 months?

Do you think the cost and time saving of not needing a phase 3 trial will add to the value? I ask that because ANP seems very undervalued and unloved in comparisome to other Bio techs in phase 2 studies, for drugs with similiar sales potentials.

24 to 36 months is a very short period of time. And we have a voucher, cost and more time savings right there.

But as you say, Time will tell. I am very happy to have bought more shares lately.